Literature DB >> 25360149

Adverse drug reactions: The importance of maintaining pharmacovigilance.

Arden R Barry1, Sheri L Koshman1, Glen J Pearson1.   

Abstract

Year:  2014        PMID： 25360149      PMCID： PMC4212444          DOI： 10.1177/1715163514536523

Source DB:  PubMed          Journal:  Can Pharm J (Ott)        ISSN： 1715-1635


× No keyword cloud information.
  11 in total

1.  Drug withdrawals from the Canadian market for safety reasons, 1963-2004.

Authors:  Joel Lexchin
Journal:  CMAJ       Date:  2005-03-15       Impact factor: 8.262

2.  Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.

Authors:  Robert S Bresalier; Robert S Sandler; Hui Quan; James A Bolognese; Bettina Oxenius; Kevin Horgan; Christopher Lines; Robert Riddell; Dion Morton; Angel Lanas; Marvin A Konstam; John A Baron
Journal:  N Engl J Med       Date:  2005-02-15       Impact factor: 91.245

Review 3.  Risk of serious adverse cardiovascular events associated with varenicline: a systematic review and meta-analysis.

Authors:  Sonal Singh; Yoon K Loke; John G Spangler; Curt D Furberg
Journal:  CMAJ       Date:  2011-07-04       Impact factor: 8.262

4.  A method for estimating the probability of adverse drug reactions.

Authors:  C A Naranjo; U Busto; E M Sellers; P Sandor; I Ruiz; E A Roberts; E Janecek; C Domecq; D J Greenblatt
Journal:  Clin Pharmacol Ther       Date:  1981-08       Impact factor: 6.875

Review 5.  Dabigatran association with higher risk of acute coronary events: meta-analysis of noninferiority randomized controlled trials.

Authors:  Ken Uchino; Adrian V Hernandez
Journal:  Arch Intern Med       Date:  2012-01-09

6.  Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.

Authors:  C Bombardier; L Laine; A Reicin; D Shapiro; R Burgos-Vargas; B Davis; R Day; M B Ferraz; C J Hawkey; M C Hochberg; T K Kvien; T J Schnitzer
Journal:  N Engl J Med       Date:  2000-11-23       Impact factor: 91.245

7.  Cardiovascular events associated with smoking cessation pharmacotherapies: a network meta-analysis.

Authors:  Edward J Mills; Kristian Thorlund; Shawn Eapen; Ping Wu; Judith J Prochaska
Journal:  Circulation       Date:  2013-12-09       Impact factor: 29.690

8.  Increased mortality after dronedarone therapy for severe heart failure.

Authors:  Lars Køber; Christian Torp-Pedersen; John J V McMurray; Ole Gøtzsche; Samuel Lévy; Harry Crijns; Jan Amlie; Jan Carlsen
Journal:  N Engl J Med       Date:  2008-06-19       Impact factor: 91.245

9.  Efficacy and safety of varenicline for smoking cessation in patients with cardiovascular disease: a randomized trial.

Authors:  Nancy A Rigotti; Andrew L Pipe; Neal L Benowitz; Carmen Arteaga; Dahlia Garza; Serena Tonstad
Journal:  Circulation       Date:  2010-01-04       Impact factor: 29.690

Review 10.  Risk of cardiovascular serious adverse events associated with varenicline use for tobacco cessation: systematic review and meta-analysis.

Authors:  Judith J Prochaska; Joan F Hilton
Journal:  BMJ       Date:  2012-05-04
View more
  2 in total

1.  A qualitative exploration of pharmacovigilance policy implementation in Jordan, Oman, and Kuwait using Matland's ambiguity-conflict model.

Authors:  Hamza Y Garashi; Douglas T Steinke; Ellen I Schafheutle
Journal:  Global Health       Date:  2021-08-30       Impact factor: 4.185

2.  Machine Learning-Based Prediction of Drug-Drug Interactions for Histamine Antagonist Using Hybrid Chemical Features.

Authors:  Luong Huu Dang; Nguyen Tan Dung; Ly Xuan Quang; Le Quang Hung; Ngoc Hoang Le; Nhi Thao Ngoc Le; Nguyen Thi Diem; Nguyen Thi Thuy Nga; Shih-Han Hung; Nguyen Quoc Khanh Le
Journal:  Cells       Date:  2021-11-09       Impact factor: 6.600
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.